Investors and Media Overview
Stock Quote: ENZN
Exchange:
NASDAQ
Price:
1.02
Change (%):
up 0.04 (4.082%)
Volume:
111,500
Data as of 4:00 PM ET on Sep 4, 2015. Delayed at least 20 minutes. Provided by eSignal.

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®.

* Enzon does not provide tax advice. Stockholders should consult with their own tax advisors regarding the specific tax treatment of the special dividend that they received from Enzon.

Recent Releases   View all »   RSS